Anti-intestinal fibrosis oral polypeptide preparation and preparation method thereof
Through the synergistic effect of probiotics and sodium alginate, an LL37 oral peptide preparation was formed, which solved the problems of drug stability and targeted delivery of intestinal tract, and achieved effective inhibition of intestinal fibrosis in inflammatory bowel disease and prevention.
Patent Information
- Application Number
- CN202411344174.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-22
AI Technical Summary
Existing drugs are difficult to effectively inhibit intestinal fibrosis, and cannot prevent or alleviate intestinal stenosis and obstruction in patients with inflammatory bowel disease. Moreover, the LL37 polypeptide is easily degraded in the stomach, making it difficult to reach the intestinal lesions.
Probiotics and antimicrobial peptides (such as LL37) are used to form a complex through charge adsorption, and sodium alginate gel is used as a protective layer to form an oral peptide preparation, using the targeted colonization of probiotics and the pH-responsive properties of sodium alginate. Achieve stable delivery and targeted gut release of LL37.
Effectively inhibit the activation of intestinal myofibroblasts and collagen secretion, reduce intestinal fibrosis, improve the stability of drugs in the stomach and the responsive release ability of intestinal inflammation in patients with inflammatory bowel disease and Level of fibrosis.
Smart Images

Figure CN118986922A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and specifically relates to an oral polypeptide preparation for resisting intestinal fibrosis and a preparation method thereof. Background Art
[0002] Intestinal fibrosis is one of the most common complications of inflammatory bowel disease (IBD). More than half of patients with IBD may progress to intestinal stenosis and obstruction in the later stages of fibrosis. Currently, the drugs used in clinical practice for IBD (aminosalicylic acids, hormones, immunosuppressants, and biological drugs) can reduce the level of intestinal inflammation in patients, but cannot change the progression of intestinal fibrosis. Once a patient develops intestinal stenosis and obstruction, surgery is necessary to relieve the symptoms of obstruction. So far, there is still a gap in drug treatment for intestinal fibrosis associated with IBD. Therefore, there is an urgent need to develop an effective drug system to prevent and reduce the level of intestinal fibrosis, prevent intestinal stenosis, and improve the quality of life of patients with IBD.
[0003] The most important pathological feature of intestinal fibrosis is the excessive proliferation and activation of intestinal myofibroblasts, which secrete a large amount of extracellular matrix (ECM). Excessive deposition of extracellular matrix leads to thickening of the intestinal wall and eventually forms intestinal stenosis. Therefore, inhibiting the excessive secretion of extracellular matrix by intestinal myofibroblasts plays an important role in the prevention and treatment of intestinal fibrosis. LL37 is the only cathelicidins family antimicrobial peptide found in the human body. It has the functions of resisting pathogenic microorganisms, neutralizing endotoxins, and regulating the balance of intestinal flora. More importantly, LL37 can effectively inhibit the activation of intestinal fibroblasts cultured in vitro from CD patient biopsy tissues and reduce the secretion of type I collagen (collagen I); in mouse models, LL37 enema can significantly resist trinitrobenzene sulfonic acid-induced intestinal fibrosis and reduce the content of intestinal ECM. The above reports suggest that LL37 is likely to have good application prospects in preventing intestinal fibrosis. However, LL37 is a polypeptide that is easily degraded by pepsin. Therefore, how to deliver biologically active LL37 to the site of intestinal lesions is a key issue in the clinical transformation of LL37. Summary of the invention
[0004] The purpose of the present invention is to provide an LL37 oral delivery system and a preparation method thereof which can orally deliver LL37 in an active form to intestinal lesions to fully exert its effect on anti-intestinal fibrosis.
[0005] The technical solution adopted by the present invention is:
[0006] An oral polypeptide preparation for resisting intestinal fibrosis, the preparation has sodium alginate gel as a protective layer, and a bacteria-LL37 complex as a core layer, which is embedded inside the protective layer; the bacteria-LL37 complex is prepared by probiotics and antimicrobial peptides through charge adsorption.
[0007] Furthermore, the probiotics have a negative charge, and the antimicrobial peptide has a positive charge.
[0008] Furthermore, the probiotics are probiotics that can regulate the balance of intestinal flora, such as Lactobacillus acidophilus, Bifidobacterium, Bacillus subtilis, Lactobacillus rhamnosus and one or more of the genetically engineered strains of the above bacteria.
[0009] The antimicrobial peptide is LL37 polypeptide or LL37 polypeptide analog.
[0010] Furthermore, the anti-intestinal fibrosis oral polypeptide preparation can be prepared by the following method:
[0011] Using probiotics as delivery carriers, the positively charged LL37 polypeptide is adsorbed onto the negatively charged probiotic surface through charge adsorption to form a bacteria-LL37 complex; the bacteria-LL37 complex is positively charged; and then using charge adsorption, negatively charged sodium alginate is deposited onto the surface of the bacteria-LL37 complex to prepare the anti-intestinal fibrosis oral polypeptide preparation.
[0012] Studies have found that the imbalance of intestinal flora and changes in metabolites play an important role in the progression of intestinal inflammation to fibrosis, promoting the pathological process of fibrosis. The supplementation of probiotics can restore the balance of intestinal flora and reduce the transformation of inflammation to fibrosis. In addition, in recent years, probiotics have been used as drug delivery carriers, and their own flora characteristics have been used to work synergistically with the drugs carried, achieving significant results. The surface of probiotics is negatively charged, and LL37 is positively charged, and the two have natural charge attraction. Based on the above, the present invention creatively proposes to use the attraction between positive and negative charges to fix LL37 on the surface of probiotics to form a bacteria-LL37 complex, and use the natural colon targeting and colonization of bacteria to achieve colon-localized delivery and retention of LL37, and use the different action pathways of the two to collaboratively block the opening of intestinal fibrosis in inflammatory bowel disease and improve chronic intestinal inflammation. However, probiotics and polypeptides are easily degraded in gastric acid and various digestive enzymes, and it is difficult for active forms to reach the intestinal lesions after oral administration. Therefore, in order to achieve efficient and coordinated oral delivery of active polypeptides and probiotics, the present invention uses a pH-responsive sodium alginate coating to encapsulate the bacteria-LL37 complex, and utilizes the characteristics of the sodium alginate coating that is stable in acid and soluble in alkaline to protect the stability of the contents in the stomach and the colon-targeted release.
[0013] The present invention also provides a method for preparing an oral polypeptide preparation for resisting intestinal fibrosis, the method comprising the following steps:
[0014] (1) Using probiotics as delivery carriers, the positively charged LL37 polypeptide is adsorbed onto the negatively charged surface of probiotics through charge adsorption to form a bacteria-LL37 complex;
[0015] (2) The bacteria-LL37 complex carries a positive charge; and then, by utilizing the charge adsorption effect, the negatively charged sodium alginate is deposited on the surface of the bacteria-LL37 complex to obtain the anti-intestinal fibrosis oral polypeptide preparation.
[0016] The bacteria-LL37 complex in step (1) is constructed by adsorption of negative charges on the surface of the bacteria and positive charges on the surface of the polypeptide. The amount of drug bound to the carrier bacteria is positively correlated with the incubation amount of the drug.
[0017] Further, the step (1) is preferably carried out according to the following steps:
[0018] The probiotics are cultured to the logarithmic phase, a probiotic solution is prepared, the LL37 polypeptide solution is dispersed in the probiotic solution, incubated for 20 to 50 minutes, centrifuged to obtain the precipitate, and washed to obtain a bacteria-LL37 complex;
[0019] The probiotic colony count and the molar number of LL37 polypeptide are fed in a ratio of 1×10 9 CFU, with a load of 222 nmol or less of LL37 polypeptide.
[0020] The concentration of the probiotics is 1×10 8 ~10 9 CFU / mL, preferably 1mL of probiotic solution.
[0021] The concentration of the LL37 polypeptide solution is preferably 22-222 nmol / mL, preferably 222 nmol / mL.
[0022] Furthermore, the preferred dosage ratio of probiotics to LL37 polypeptide is 1×10 9 CFU: 222nmol.
[0023] The incubation time is preferably 30 min. PBS buffer is preferably used for washing.
[0024] Further, the step (2) is preferably carried out according to the following steps:
[0025] The bacteria-LL37 complex obtained in step (1) is suspended in a 1-10 mg / mL sodium alginate solution, incubated for 10-20 minutes, and then centrifuged to wash the precipitate to obtain a sodium alginate-coated bacteria-LL37 complex, which is the anti-intestinal fibrosis oral polypeptide preparation.
[0026] The concentration of the sodium alginate solution is preferably 5 mg / mL.
[0027] The sodium alginate solution is preferably prepared using 0.5-1 wt % (more preferably 0.9 wt %) sodium chloride solution as solvent.
[0028] The mass ratio of the probiotic colony count to the sodium alginate in the bacteria-LL37 complex is 1×10 8 ~10 9 CFU (measured in bacteria): 5mg.
[0029] The precipitate can generally be washed with physiological saline.
[0030] The particle size of the anti-intestinal fibrosis oral polypeptide preparation prepared by the invention is 1 μm to 10 μm.
[0031] The beneficial effects of the present invention are:
[0032] (1) In the present invention, LL37, which has anti-intestinal fibrosis efficacy in vitro, is used as a model drug, an oral delivery system of LL37 is constructed, and drug treatment of intestinal tissue fibrosis is explored.
[0033] (2) Probiotics are used as oral delivery carriers to achieve the synergistic effect of probiotics and active peptides, regulate the balance of intestinal flora, and prevent the transformation of inflammation into fibrosis, providing a new idea for the prevention and treatment of intestinal fibrosis.
[0034] (3) The sodium alginate coating is used for solidification. The sodium alginate coating is stable in acid and soluble in alkaline solution, which increases the stability of live bacteria and polypeptides in the stomach and the intestinal responsive release capacity. In addition, sodium alginate is a prebiotic that can be further decomposed into short-chain fatty acids to exert a synergistic anti-fibrosis effect. The oral polypeptide preparation is constructed through charge adsorption, which does not affect the activity of probiotics and polypeptides; at the same time, it achieves complementary synergistic effects, providing a possibility for the prevention and treatment of intestinal fibrosis.
[0035] At present, there is no LL37-responsive oral preparation based on probiotics as delivery carriers for intestinal anti-fibrosis treatment on the market, nor is there any research report on similar pharmaceutical preparations. The oral anti-intestinal fibrosis polypeptide preparation provided by the present invention not only has important clinical significance, but also has broad market prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The morphology of Lactobacillus acidophilus is shown in Figure 5. Scale bar = 5 μm.
[0037] Figure 2 This is the potential distribution diagram of LL37.
[0038] Figure 3 This is an electron micrograph of an oral Lactobacillus acidophilus peptide preparation, scale bar = 2 μm.
[0039] Figure 4 This is a graph showing the in vitro anti-fibrotic effect of an oral Lactobacillus acidophilus peptide preparation.
[0040] Figure 5 The figure shows the in vivo anti-fibrotic effect of oral Lactobacillus acidophilus peptide preparation.
[0041] Figure 6 This is a VG staining image of intestinal tissue.
[0042] Figure 7 This is a graph showing the in vitro anti-fibrotic effect of an oral Bifidobacterium-peptide preparation. DETAILED DESCRIPTION
[0043] The present invention is further described by the following examples, but the protection scope of the present invention is not limited thereto.
[0044] Example 1: This example is an oral Lactobacillus acidophilus peptide preparation for preventing intestinal fibrosis.
[0045] 1. In vitro culture of Lactobacillus acidophilus: Weigh the MRS culture medium and sterilize it at 121℃ for 15 minutes. Fully dissolve the solid Lactobacillus acidophilus powder with sterile water, spread it on the solid culture medium, place it in an anaerobic environment, and culture it at 37℃ for 48 hours. Use a bamboo stick to pick up a small amount of bacteria, streak it on a new culture plate, and culture it for another 48 hours. At this time, the bacteria are activated and can be used. Then use an inoculation loop to pick up a single colony into the liquid MRS culture medium and culture it in a shaker at 37℃ for 48 hours. Take the bacterial solution and dilute it appropriately, drop it on a glass slide, stand the glass slide upright, let the liquid spread naturally and air-dry naturally, take a picture, and the morphology of Lactobacillus acidophilus is as follows Figure 1 As shown, a single bacterium is approximately 1-5 μm.
[0046] 2. LL37 potential determination: Prepare 1 mg / mL LL37 peptide solution, and use Malvern particle size potential meter to measure LL37 potential. The measured LL37 potential is +10.7mv. The result is as follows: Figure 2 shown.
[0047] 3. Preparation of oral Lactobacillus acidophilus-peptide preparation: Take 5 mL (about 1.0×10 9CFU), centrifuge at 4000rpm for 10min, collect bacteria, wash once with 5mL normal saline, collect bacteria, and resuspend with 1mL normal saline. Prepare 1mL of 222nmol / mL LL37 solution, add it to the above-mentioned bacterial solution, incubate at room temperature for half an hour (shake gently), centrifuge at 4000rpm for 10min, collect bacteria, wash 3 times with PBS buffer to obtain Lactobacillus acidophilus-LL37 complex. Prepare 5mg / mL sodium alginate solution with 0.9% sodium chloride solution. Resuspend the above-mentioned Lactobacillus acidophilus-LL37 complex precipitation obtained with 1mL sodium alginate solution, incubate on a shaking table for 10 minutes, centrifuge at 8000rpm for 10 minutes, collect precipitation, wash 2-3 times with normal saline to wash away residual free sodium alginate, collect precipitation, and oral Lactobacillus acidophilus-peptide preparation can be obtained.
[0048] 4. Determination of LL37 adsorption capacity: Take 5 mL (1.0×10 9 CFU), centrifuged at 4000rpm for 10min, collected the cells, washed once with 5mL of saline, collected the cells, and resuspended with 1mL of saline. Prepare 1mL of 222nmol / mL LL37 solution, add it to the above bacterial solution, incubate at room temperature for half an hour (shake gently), centrifuge at 4000rpm for 10min, and collect the supernatant. Wash the cell precipitate with PBS 3 times, centrifuge, collect the supernatant in a test tube, and use high performance liquid chromatography to detect the LL37 content to obtain the unloaded LL37 content, and then calculate the Lactobacillus acidophilus 1×10 9 CFU, approximately 190 nmol of LL37 was loaded.
[0049] 5. Electron microscopic observation of oral Lactobacillus acidophilus-peptide preparation: 1 mL of oral Lactobacillus acidophilus-peptide preparation was applied to a copper grid, and after drying, the morphology was observed using an electron microscope. The results are as follows: Figure 3 .
[0050] 6. In vitro anti-fibrosis study: Intestinal fibroblasts were obtained and inoculated into 6-well plates. The control group was treated with normal saline, the model group was pretreated with TGF-β1, and the drug-treated group was pretreated with TGF-β1 and added with Lactobacillus acidophilus-LL37 complex. The mRNA of Col I in different drug-treated groups was detected by qRT-PCR. The results are shown in Figure 4 .Depend on Figure 4 It can be seen that after treatment with the Lactobacillus acidophilus-LL37 complex, the mRNA expression of Col I in intestinal myofibroblasts was significantly decreased, indicating that the Lactobacillus acidophilus-LL37 complex has a significant anti-fibrotic effect in vitro.
[0051] 7. In vivo anti-fibrosis investigation: A total of 24 C57BL / 6 mice aged 6-8 weeks were selected and divided into 4 groups after one week of adaptive feeding: healthy group, model group, free LL37 group and bacterial preparation group. The model group, free LL37 group and bacterial preparation group mice used DSS to construct a chronic intestinal inflammatory fibrosis model. The specific scheme is as follows: After the mice drank 2.0% DSS (w / v) for 1 week, they switched to pure water for 2 weeks. This scheme lasted for 3 cycles, a total of 63 days. The mice in the healthy group always drank pure water. At the beginning of modeling, the mice in the drug-treated group were orally gavaged with normal saline, free LL37 (20 mg / kg), and the Lactobacillus acidophilus-peptide preparation prepared in step 3 every other day (converted according to the LL37 dosage of 20 mg / kg). After the end of the drug administration, the mice were euthanized, and the intestinal tissue was removed for length measurement. The results showed that compared with the healthy group, the intestine of the mice in the model group was significantly shortened, the free LL37 group did not significantly retain the length of the colon, and the Lactobacillus acidophilus-peptide preparation could significantly retain the length of the mouse intestine ( Figure 5 ).
[0052] 8. Van Gieson (VG) staining observation: The colon tissues of different groups were fixed in 4% formalin solution for 48 hours and then embedded in paraffin. The paraffin sections were stained with VG and observed under an optical microscope ( Figure 6 ). Colon sections in the healthy group showed that the intestinal tissue was neatly arranged, the morphology and structure were intact, and the amount of collagen deposition was normal. Tissue sections in the model group showed that the intestinal structure was severely damaged, accompanied by a significant increase in extracellular matrix. The free LL37 group did not significantly improve the pathological structure of the colon, and collagen deposition was more obvious. Intestinal tissue sections in the group administered with the Lactobacillus acidophilus-peptide preparation showed that the intestinal tissue was neatly arranged, the morphology was basically intact, and the collagen deposition content was significantly reduced.
[0053] Example 2: This example is an oral Bifidobacterium-peptide preparation for preventing intestinal fibrosis prepared by the method provided by the present invention.
[0054] 1. In vitro culture of bifidobacteria: Weigh MRS culture medium and sterilize at 121℃ for 15 minutes. Dissolve solid bifidobacterium powder with sterile water, apply it on solid culture medium, place it in an anaerobic environment, and culture it at 37℃ for 48h. Use a bamboo stick to pick up a small amount of bacteria, streak it on a new culture plate, and culture it for another 48h. At this time, the bacteria are activated and can be used. Then use an inoculation loop to pick a single colony into liquid MRS culture medium and culture it at 37℃ in a shaker for 48h.
[0055] 2. Preparation of oral bifidobacterium-peptide preparation: Take 5 mL (about 1.0×10 9CFU), centrifuged at 4000rpm for 10min, collected the cells, washed once with 5mL of normal saline, collected the cells, and resuspended with 1mL of normal saline. Prepare 1mL of 222nmol / mL LL37 solution, add it to the above-mentioned cells, incubate at room temperature for half an hour (shake gently), centrifuged at 4000rpm for 10min, collected the cells, washed 3 times with PBS buffer, and obtained a bifidobacterium-LL37 complex precipitate. Prepare 5mg / mL sodium alginate solution with 0.9% sodium chloride solution. Resuspend the above-obtained bifidobacterium-LL37 complex precipitate with 1mL of sodium alginate solution, incubate on a shaking table for 10 minutes, centrifuge at 8000rpm for 10 minutes, collect the precipitate, wash 2-3 times with normal saline, wash away the residual free sodium alginate, collect the precipitate, and obtain an oral bifidobacterium-peptide preparation.
[0056] 3. In vitro anti-fibrosis study: Intestinal fibroblasts were obtained and inoculated into 6-well plates. The control group was treated with normal saline, the model group was pretreated with TGF-β1, and the drug-treated group was pretreated with TGF-β1 and added with Bifidobacterium-LL37 complex. The mRNA of Col I in different drug-treated groups was detected by qRT-PCR. The results are shown in Figure 7 .Depend on Figure 7 It can be seen that after treatment with the Bifidobacterium-LL37 complex, the mRNA expression of Col I in intestinal myofibroblasts was significantly decreased, indicating that the Bifidobacterium-LL37 complex has a significant anti-fibrotic effect in vitro.
[0057] The preferred embodiments and principles of the present invention are described in detail above. For those skilled in the art, according to the ideas provided by the present invention, there may be changes in the specific implementation methods, and these changes should also be regarded as the protection scope of the present invention.
Claims
1. An oral polypeptide preparation for preventing intestinal fibrosis, Features The anti-intestinal fibrosis oral polypeptide preparation uses sodium alginate gel as a protective layer and a bacteria-LL37 complex as a core layer, which is embedded inside the protective layer; the bacteria-LL37 complex is prepared by probiotics and antimicrobial peptides through charge adsorption.
2. The anti-intestinal fibrosis oral polypeptide preparation according to claim 1, Features The probiotics have a negative charge, and the antimicrobial peptides have a positive charge.
3. The anti-intestinal fibrosis oral polypeptide preparation according to claim 1, Features The probiotics are probiotics that regulate the balance of intestinal flora, and the antimicrobial peptide is LL37 polypeptide or LL37 polypeptide analog.
4. The anti-intestinal fibrosis oral polypeptide preparation according to claim 3, Features The probiotics are one or more of Lactobacillus acidophilus, Bifidobacterium, Bacillus subtilis, Lactobacillus rhamnosus and genetically engineered strains of the above bacteria.
5. The anti-intestinal fibrosis oral polypeptide preparation according to any one of claims 1 to 4, Features The anti-intestinal fibrosis oral polypeptide preparation is prepared by the following method: Using probiotics as delivery carriers, the positively charged LL37 polypeptide is adsorbed onto the negatively charged probiotic surface through charge adsorption to form a bacteria-LL37 complex; the bacteria-LL37 complex is positively charged; and then using charge adsorption, negatively charged sodium alginate is deposited onto the surface of the bacteria-LL37 complex to prepare the anti-intestinal fibrosis oral polypeptide preparation.
6. A method for preparing the anti-intestinal fibrosis oral polypeptide preparation according to any one of claims 1 to 4, Features The method comprises the following steps: (1) Using probiotics as delivery carriers, the positively charged LL37 polypeptide is adsorbed onto the negatively charged surface of probiotics through charge adsorption to form a bacteria-LL37 complex; (2) The bacteria-LL37 complex carries a positive charge; and then, by utilizing the charge adsorption effect, the negatively charged sodium alginate is deposited on the surface of the bacteria-LL37 complex to obtain the anti-intestinal fibrosis oral polypeptide preparation.
7. The method according to claim 6, Features The step (1) is carried out according to the following steps: The probiotics are cultured to the logarithmic phase, a probiotic solution is prepared, the LL37 polypeptide solution is dispersed in the probiotic solution, incubated for 20 to 50 minutes, centrifuged to obtain the precipitate, and washed to obtain a bacteria-LL37 complex.
8. The method according to claim 7, Features The feeding ratio of the probiotic colony count to the LL37 polypeptide molar number is 1×10 9 CFU, with a load of less than or equal to 222 nmol of LL37 polypeptide.
9. The method according to claim 6, Features The step (2) is carried out according to the following steps: The bacteria-LL37 complex obtained in step (1) is suspended in a 1-10 mg / mL sodium alginate solution, incubated for 10-20 minutes, and then centrifuged to wash the precipitate to obtain a sodium alginate-coated bacteria-LL37 complex, which is the anti-intestinal fibrosis oral polypeptide preparation.
10. The method according to claim 6, Features The mass ratio of the probiotic colony count to the sodium alginate in the bacteria-LL37 complex is 1×10 8 ~10 9 CFU:5mg.
Citation Information
Cited By
Biological coating coated probiotics as well as preparation method and application thereof
CN119925296A
